SUDOSCAN's Benefits for Early Diagnosis of Diabetic Peripheral Neuropathy Reviewed in The Lancet
Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, Tesfaye S.
Article title: “Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention”.
The Lancet Diabetes Endocrinol 2019. Volume 7, Issue 12, p938-948, December 01, 2019.
A recent review has been published in The Lancet Diabetes & Endocrinology, showing the utility
of SUDOSCAN in the early diagnosis of diabetic peripheral neuropathy (DPN).
Early detection of DPN is a key point in the management of diabetic patients; indeed, DPN is a principal cause of diabetic foot ulceration and can lead to foot amputation.
As DPN is a marker of diabetic complications, the authors propose using point-of-care testing to screen for various diabetes complications in a single visit. Large and small fiber assessments (DPN-Check and SUDOSCAN, respectively) can be performed easily to identify neuropathies as shown in the pattern below.
Clinical utility of SUDOSCAN for the diagnosis of diabetic peripheral neuropathy: sensivity 87,5%, specificity 76,2%, intra-observer intraclass correlation coefficient 0,88 and inter-observer intraclass correlation coefficient 0,95.
Proposed assessments for a one-stop screening clinic for diabetes complications,
including use of point-of-care devices for DPN
Adapted from Binns-Hall and colleagues, by permission of the authors. DPN=diabetic peripheral neuropathy. PHQ-9=Patient Health Questionnaire-9. NAFLD=non-alcoholic fatty liver disease. LFTs=liver function tests. ACR=urine albumin-to-creatinine ratio. U&E=urea and electrolytes. eGFR=estimated glomerular filtration rate.